Symbiotec Pharmalab
Symbiotec Pharmalab is a pharmaceutical and biotechnology company specializing in the manufacture of Corticosteroid and Steroidal Hormone APIs. The company operates as a fully integrated global player within the pharmaceutical ingredients sector.
Price Band
₹938 - ₹988
Lot Size
15 Shares
Issue Size
₹1,757.00 Cr
Fresh Issue
₹150.00 Cr
OFS
₹1,607.00 Cr
Registrar
AI Sentiment Score
Current GMP
+₹325
Est. Listing: ₹1,313 (+32.9%)
📅 IPO Timeline
1
Open
Aug 24
2
Close
Aug 27
3
Allotment
Aug 28
4
Refund
Aug 31
5
Demat
Aug 31
6
Listing
Sep 1
✨ AI Analysis & Prediction
+20.7%
predicted listing gain
The predicted listing gain is adjusted downward from the GMP baseline due to a heavy Offer for Sale (OFS) structure (91.5%) and modest ROE/ROCE figures. However, strong revenue growth and a leading global position in steroid APIs provide a fundamental floor that prevents a deeper correction.
💪 Strengths
- Global leader by volume in Corticosteroid and Steroidal-Hormone APIs
- Only Indian company present across top 10 global categories in its market
⚠️ Weaknesses
- High Offer for Sale (OFS) component relative to fresh issue
- Modest ROE (11.19%) compared to industry leaders
🚀 Opportunities
- Expansion of global pharmaceutical demand for steroid-based medicines
- Further deleveraging using IPO proceeds
🛡️ Threats
- Intense competition from global API manufacturers
- Regulatory risks associated with pharmaceutical manufacturing standards
🎯 Objectives of the IPO
| Requirement / Purpose | Amount (₹ Cr) |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | ₹112.50 |
| General corporate purposes | ₹1,644.50 |
📊 Financial Overview
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | Rs 716.00 Cr | Rs 752.00 Cr | Rs 869.00 Cr |
| Net Profit / PAT (₹ Cr) | Rs 100.00 Cr | Rs 97.00 Cr | Rs 110.00 Cr |
| EBITDA / Op. Profit (₹ Cr) | Rs 172.00 Cr | Rs 203.00 Cr | Rs 238.00 Cr |
| Borrowings (₹ Cr) | Rs 247.00 Cr | Rs 541.00 Cr | NA |
| Total Assets (₹ Cr) | Rs 1,289.00 Cr | Rs 1,579.00 Cr | NA |
| ROCE % | 16.00% | 14.00% | NA |
📋 Live Subscription Status
QIB
0.00x
NII
0.00x
Retail
0.00x
Total
0.00x
Updated: Aug 22, 2026 8:02 AM
💼 Reservation Quota
QIB
50.00%
Retail
35.00%
NII
15.00%
📈 Shareholding & Anchor Lock-In
🔗 Important Links & Lead Managers
- Registrar WebsiteVisit →
- Download DRHP ProspectusDownload PDF 📥
- Download RHP ProspectusDownload PDF 📥
Lead Managers / Merchant Bankers
This issue is managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd.
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.
Symbiotec Pharmalab possesses over 30 years of industrial experience, having evolved from a small laboratory-scale steroid manufacturer into a fully integrated global entity. The company's core business model revolves around the development and production of Active Pharmaceutical Ingredients (APIs), specifically targeting the Corticosteroid and Steroidal Hormone markets.
In FY2025, the company achieved a significant milestone by becoming a global leader by volume in the production of these specific APIs. Notably, Symbiotec is the only Indian and global company to maintain a presence across the top 10 categories within this specialized market, underscoring its technical depth and product diversity.
The company's operational scale is reflected in its steady asset growth, reaching ₹1,780.79 crores by 2026. Its business model leverages high-barrier-to-entry chemistry to serve global pharmaceutical markets, ensuring a steady demand for its steroid-based ingredients used in various medicines.
The company is led by a promoter group consisting of Anil Satwani, Kashish Satwani, Sushil Satwani, and Satwani Holdings LLP. Their leadership has transitioned the company from a domestic player to a global leader in the steroidal hormone API segment.
The Symbiotec Pharmalab IPO is a mainboard issue seeking to raise approximately ₹1,757 crores. The issue is structured with a fresh issue of ₹150 crores and a substantial Offer for Sale (OFS) of approximately 1,62,65,181 equity shares. The price band is set between ₹938 and ₹988 per share, with a minimum retail lot size of 15 shares. The IPO opens on August 24, 2026, and closes on August 27, 2026, with listing on the BSE and NSE scheduled for September 1, 2026.
Proceeds from the fresh issue are primarily earmarked for the repayment or prepayment of outstanding borrowings, totaling ₹112.50 crores, indicating a focus on deleveraging the balance sheet. The remaining funds are allocated toward general corporate purposes.
Financial performance has shown a positive trajectory. Revenue grew from ₹723.33 crores in 2024 to ₹872.26 crores in 2026. Net Profit (PAT) followed a similar upward trend, recovering from ₹96.79 crores in 2025 to ₹109.90 crores in 2026. The company maintains a healthy EBITDA margin of 26.59% and a PAT margin of 12.60%.
From a valuation perspective, the company reports an EPS of ₹19.10 and a Net Asset Value (NAV) of ₹184.69. While peer comparisons with companies like Concord Biotech and Divi's Laboratories show higher P/E ratios in the sector, the high OFS component of this issue may be viewed by some investors as a promoter offloading event, which typically acts as a sentiment drag.
Investment strengths include its global volume leadership in steroid APIs and consistent top-line growth. However, the primary risk is the heavy OFS weight (over 90% of the issue), which means very little new capital is entering the company relative to the total shares being sold. Investors should weigh the global market leadership against the structural nature of the IPO.